Abstract
TAFRO syndrome is characterized by the presence of thrombocytopenia, anasarca, fever, reticular myelofibrosis, organomegaly, and is frequently associated with kidney damage in the form of membranoproliferative glomerulonephritis (MPGN) or thrombotic microangiopathy (TMA). Treatment is based on corticosteroids. A 59-year-old man who suffered from heart disease, pancytopenia and hepatosplenomegaly of unknown etiology developed nephrotic syndrome and progressive renal insufficiency, with a kidney biopsy suggestive of MPGN with a “full-house” immunofluorescence pattern. Positron emission tomography (PET) revealed multiple lymphadenopathies which histologically were compatible with multicentric Castleman's disease. The patient was diagnosed with TAFRO syndrome and treatment with siltuximab was started, with evident improvement at 3 months. TAFRO syndrome is a rare entity which may present with severe kidney involvement and histological findings of MPGN or TMA, with or without immune complex deposits. Our case suggests that a corticosteroid-free regimen with siltuximab could be an attractive therapeutic option.
This is a preview of subscription content, log in via an institution to check access.
References
Takai K, Nikkuni K, Shibuya H et al (2010) Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Rinsho Ketsueki 51:320–325
Ito S, Uchida T, Itai H, Yamashiro A, Yamagata A, Matsubara H, Imakiire T, Shimazaki H, Kumagai H, Oshima N (2018) Serial manifestation of acute kidney injury and nephrotic syndrome in a patient with TAFRO syndrome. Intern Med 57(21):3129–3133
Shimada K, Sasaki T, Okabe M et al (2021) TAFRO syndrome with kidney involvement: a case series of patients with kidney biopsies. Kidney Med 3:286–293
Masaki Y, Kawabata H, Takai K et al (2016) Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome. Int J Hematol 103:686–692
Masaki Y, Kawabata H, Takai K, Tsukamoto N, Fujimoto S, Ishigaki Y, Kurose N, Miura K, Nakamura S, Aoki S; Japanese TAFRO Syndrome Research Team. 2019 updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol. 2020;111(1):155–158. https://doi.org/10.1007/s12185-019-02780-1(Epub 2019 Nov 28. PMID: 31782045).
Masaki Y, Kawabata H, Fujimoto S et al (2019) Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan. J Clin Exp Hematop 59:175–178
Iwaki N, Fajgenbaum DC, Nabel CS et al (2016) Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91:220–226
Mizuno H, Sawa N, Watanabe S et al (2020) The clinical and histopathological feature of renal manifestation of TAFRO syndrome. Kidney Int Rep 5:1172–1179
Leurs A, Gnemmi V, Lionet A et al (2019) Renal pathologic findings in TAFRO syndrome: is there a continuum between thrombotic microangiopathy and membranoproliferative glomerulonephritis? A case report and literature review. Front Immunol 10:1489
Zhou Q, Zhang Y, Zhou G et al (2020) Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature. BMC Nephrol 21:499
D’Agati VD, Stokes MB. Renal disease in systemic lupus erythematosus, mixed connective tissue disease, Sjögren syndrome, and rheumatoid arthritis. In: Jennette JC, Olson JL, Silva FG, D’Agati VD, editors. Hepinstall's Pathology of Kidney. 7th ed. Philadelphia: Lippincott Williams and Wilkins; 2014.
Paydas S (2018) Tafro syndrome: critical review for clinicians and pathologists. Crit Rev Oncol Hematol 128:88–95
Shirai T, Onishi A, Waki D et al (2018) Successful treatment with tacrolimus in TAFRO syndrome: two case reports and literature review. Medicine (Baltimore) 97:e11045
Fajgenbaum DC, Langan RA, Japp AS et al (2019) Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Investig 129:4451–4463
Igawa T, Sato Y (2018) TAFRO Syndrome. Hematol Oncol Clin NAm 32:107–118
Acknowledgements
The authors would like to acknowledge Dr. Hernando Trujillo for his generous advice, advisory work and translation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors of this manuscript have no conflicts of interest to declare.
Patient consent
The authors obtained informed consent from the patient discussed in the report.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Cordero, L., Aguilar-Rodríguez, F., Sandino, J. et al. Siltuximab Monotherapy in Tafro Syndrome: A Case Report and Review of the Literature. J Nephrol 36, 1181–1185 (2023). https://doi.org/10.1007/s40620-022-01517-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40620-022-01517-4